Skip to main content
Full access
Letters to the Editor
Published Online: 1 January 2009

Antipsychotic Properties of Muscarinic Drugs

To the Editor: We read with great interest the article by Anantha Shekhar, M.D., Ph.D. et al. (1), published in the August 2008 issue of the Journal, which stated that the muscarinic receptor agonist xanomeline improved schizophrenia symptoms overall, although one patient in the study showed worsening of psychotic symptoms.
We previously reported that physostigmine, a reversible centrally acting cholinesterase inhibitor, muted symptoms in schizophrenia patients (2) . In our study, we examined eight floridly symptomatic schizophrenia patients who did not show marked affective symptoms, six acutely ill schizoaffective disorder patients, two depressed patients, and eight mania patients. A blunting of psychotic symptoms was observed among schizophrenia patients, and thus their delusions, hallucinations, and bizarre behavior qualitatively continued, although these symptoms were in muted form following administration of physostigmine. After receiving physostigmine, one patient, who claimed to possess telepathy with God, said “God is still talking to me, yet softly.” Additionally, physostigmine antagonized manic symptoms and induced depression in patients who had schizophrenia with an affective component. We subsequently demonstrated that physostigmine-induced behavioral, cardiovascular, and endocrine phenomena are antagonized by scopolamine, indicating central muscarinic phenomena (3) .
We have also observed that the dramatic psychosis activating effects of intravenous methylphenidate, a dopaminergic psychostimulant, were antagonized by physostigmine when administered subsequent to methylphenidate and prevented when followed by methylphenidate (4), which are findings consistent with preclinical studies (5) . Treatment with physostigmine reversed mania but resulted in depressed patients becoming more depressed. Based on our results, we proposed a catecholaminergic-cholinergic balance hypothesis for schizophrenia (4) that is consistent with the results of the study conducted by Dr. Shekhar et al.
Finally, we recommend caution, since Rowntree et al. (6) administered diisopropylfluorophosphonate, a centrally active cholinesterase inhibitor, to patients with schizophrenia, mania, and depression and to healthy comparison subjects and observed a consistent dramatic and long-lasting activation of severe psychotic symptoms among six out of 17 schizophrenia patients, with one improving and 10 not changing. This activation of symptoms is consistent with findings from the early preclinical study of rats conducted by Fibiger et al. (7), which suggested a compensatory catecholaminergic rebound following physostigmine-induced locomotor inhibition.

Footnotes

The authors report no competing interests.
This letter (doi: 10.1176/appi.ajp.2008.08091384) was accepted for publication in October 2008.

References

1.
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC: Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165:1033–1039
2.
Janowsky DS, el-Yousef MK, Davis JM: Acetylcholine and depression. Psychosom Med 174; 36:248–257
3.
Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey L: Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary, and adrenal neuroendocrine release. Psychopharmacology 1986; 89:150–154
4.
Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ: Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 1973; 130:1370–1376
5.
Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ: Cholinergic antagonism of methylphenidate-induced stereotyped behavior. Psychopharmacologia 1972; 27:295–303
6.
Rowntree DW, Nevin S, Wilson A: The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol Neurosurg Psychiatry 1950; 13:47–62
7.
Fibiger HD, Lynch GS, Cooper HP: A biphasic action of central cholinergic stimulation on behavioral arousal in the rat. Psychopharmacologia 1971; 20:366–382

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 110
PubMed: 19122017

History

Published online: 1 January 2009
Published in print: January, 2009

Authors

Details

DAVID S. JANOWSKY, M.D.
JOHN M. DAVIS, M.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share